Oruka Therapeutics (NASDAQ:ORKA) Trading 5% Higher Following Analyst Upgrade

Key Points

• Shares rose about 5% after UBS raised its price target to $75 and maintained a buy rating, with the stock trading up to $59.20 on slightly above-average volume.
• Analyst sentiment is broadly positive — 10 Buy vs. 1 Sell — with a consensus price target of $62.10 and individual targets ranging as high as $86.
• Insiders have sold recent stock (23,765 shares worth ~$849,575 over three months) but still own 24.69% while institutions hold 56.44%; Oruka is a clinical‑stage biotech (market cap ≈ $2.95B) with lead candidate ONCT‑01 in Phase 1.

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) were up 5% on Tuesday after UBS Group raised their price target on the stock from $50.00 to $75.00. UBS Group currently has a buy rating on the stock. Oruka Therapeutics traded as high as $58.53 and last traded at $59.20. Approximately 623,149 shares changed hands during trading, an increase of 7% from the average daily volume of 584,512 shares. The stock had previously closed at $56.37.

Other analysts also recently issued reports about the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Barclays lifted their price objective on Oruka Therapeutics from $48.00 to $50.00 and gave the company an "overweight" rating in a research note on Friday, March 13th. Piper Sandler started coverage on Oruka Therapeutics in a research note on Thursday, December 18th. They set an "overweight" rating and a $75.00 price objective for the company. Guggenheim restated a "buy" rating and set a $60.00 price target on shares of Oruka Therapeutics in a research report on Friday, March 13th. Finally, Leerink Partners lifted their price objective on Oruka Therapeutics from $58.00 to $86.00 and gave the stock an "outperform" rating in a report on Monday, March 16th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Oruka Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $62.10.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the sale, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Joana Goncalves sold 7,641 shares of the business's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31. Following the completion of the transaction, the insider directly owned 33,377 shares in the company, valued at $1,365,453.07. This trade represents a 18.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 23,765 shares of company stock worth $849,575 over the last three months. Insiders own 24.69% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Fairmount Funds Management LLC raised its stake in Oruka Therapeutics by 9.9% in the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company's stock worth $71,252,000 after buying an additional 333,340 shares in the last quarter. Viking Global Investors LP bought a new position in Oruka Therapeutics in the third quarter worth approximately $51,280,000. Deep Track Capital LP raised its stake in Oruka Therapeutics by 38.4% in the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company's stock worth $51,051,000 after buying an additional 735,983 shares in the last quarter. Vanguard Group Inc. raised its stake in Oruka Therapeutics by 38.1% in the fourth quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company's stock worth $74,366,000 after buying an additional 676,865 shares in the last quarter. Finally, RTW Investments LP raised its stake in Oruka Therapeutics by 5.8% in the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company's stock worth $62,382,000 after buying an additional 112,499 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Stock Performance

The firm has a fifty day moving average price of $37.40 and a 200 day moving average price of $31.02. The stock has a market cap of $2.95 billion, a PE ratio of -31.99 and a beta of -0.54.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.16. On average, equities research analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.